Oxaliplatin/5-fluorouracil-based adjuvant chemotherapy as a standard of care for colon cancer in clinical practice: Outcomes of the ACCElox registry

Asia-Pacific Journal of Clinical Oncology

Volumn 11, Issue 4, 2015, Pages 334-342

  Park, Young Suk ^a   Ji, Jiafu ^b   Zalcberg, John Raymond ^c   El Serafi, Mostafa ^d   Buzaid, Antonio ^e   Ghosn, Marwan ^f  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

^c PETER MACCALLUM CANCER CENTRE   (Australia)

^d CAIRO UNIVERSITY   (Egypt)

^e HOSPITAL SÍRIO LIBANÊS   (Brazil)

^f SAINT JOSEPH UNIVERSITY   (Lebanon)

Author keywords

Adjuvant chemotherapy; Neutropenia; Oxaliplatin; Sensory neuropathy; Thrombocytopenia

Indexed keywords

CAPECITABINE; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN; ANTINEOPLASTIC AGENT; PLATINUM COMPLEX;

ADULT; AGED; ANOREXIA; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CENTRAL NERVOUS SYSTEM DISEASE; COLON CANCER; COLON RESECTION; CONSTIPATION; CONTROLLED STUDY; DEATH; DIARRHEA; DISEASE FREE SURVIVAL; DRUG DOSE REDUCTION; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OBSERVATIONAL STUDY; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SENSORY NEUROPATHY; THERAPY DELAY; THROMBOCYTOPENIA; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; ADJUVANT CHEMOTHERAPY; ADOLESCENT; CLINICAL PRACTICE; CLINICAL TRIAL; COLONIC NEOPLASMS; HEALTH CARE QUALITY; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PATHOLOGY; PROGNOSIS; SURVIVAL RATE; TUMOR RECURRENCE; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; COLONIC NEOPLASMS; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; PRACTICE PATTERNS, PHYSICIANS'; PROGNOSIS; PROSPECTIVE STUDIES; STANDARD OF CARE; SURVIVAL RATE; YOUNG ADULT;

EID: 84944715546     PISSN: 17437555     EISSN: 17437563     Source Type: Journal    
DOI: 10.1111/ajco.12409     Document Type: Article

References (24)

1. Moghimi-Dehkordi B, Safaee A. An overview of colorectal cancer survival rates and prognosis in Asia. World J Gastrointest Oncol 2012; 4: 71-75.
2. Stein A, Quidde J, Arnold D. Oxaliplatin for colorectal cancer: recent evidence from clinical trials. Colorectal Cancer 2013; 2: 135-144.
3. Hogan NH, Joyce MR. Surgical management of locally recurrent rectal cancer. Int J Surg Oncol 2012; 2012: 464380.
4. You YT, Chang Chien CR, Wang JY etal. Evaluation of contrast-enhanced computed tomographic colonography in detection of local recurrent colorectal cancer. World J Gastroenterol 2005; 12: 123-126.
5. Lemos C, Sack U, Schmid F etal. Anti-metastatic treatment in colorectal cancer: targeting signaling pathways. Curr Pharm Des 2013; 19: 841-863.
6. Satram-Hoang S, Lee L, Yu S etal. Comparative effectiveness of chemotherapy in elderly patients with metastatic colorectal cancer. J Gastrointest Cancer 2013; 44: 79-88.
7. De Dosso S, Sessa C, Saletti P. Adjuvant therapy for colon cancer: present and perspectives. Cancer Treat Rev 2009; 35: 160-166.
8. Demols A, Van Laethem JL. Adjuvant chemotherapy for colorectal cancer. Curr Gastroenterol Rep 2002; 4: 420-426.
9. Hobday TJ. An overview of approaches to adjuvant therapy for colorectal cancer in the United States. Clin Colorectal Cancer 2005; 5: S11-18.
10. Carrato A. Adjuvant treatment of colorectal cancer. Gastrointest Cancer Res 2008; 2: S42-46.
11. Zouhairi ML, Charabaty A, Pishvaian MJ. Molecularly targeted therapy for metastatic colon cancer: proven treatments and promising new agents. Gastrointest Cancer Res 2011; 4: 15-21.
12. Rao S, Cunningham D, Price T etal. Phase II study of capecitabine and mitomycin C as first-line treatment in patients with advanced colorectal cancer. Br J Cancer 2004; 91: 839-843.
13. André T, Boni C, Navarro M etal. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 2009; 27: 3109-3116.
14. Kuebler JP, Wieand HS, O'Connell MJ etal. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol 2007; 25: 2198-2204.
15. Cassidy J, Tabernero J, Twelves C etal. XELOX (Capecitabine Plus Oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol 2004; 22: 2084-2091.
16. Haller DG, Tabernero J, Maroun J etal. Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. J Clin Oncol 2011; 29: 1465-1471.
17. Yothers G, O'Connell MJ, Allegra CJ etal. Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses. J Clin Oncol 2011; 29: 3768-3774.
18. Sanoff HK, Carpenter WR, Martin CF etal. Comparative effectiveness of oxaliplatin versus non-oxaliplatin-containing adjuvant chemotherapy for stage III Colon cancer. J Natl Cancer Inst 2012; 104: 211-227.
19. Howlader N, Noone AM, Krapcho M etal. SEER Cancer Statistics Review (CSR), 1975-2010. [Cited 13 Dec 2013.] Available from URL: http://seer.cancer.gov/csr/1975_2010/.
20. Milosevic DP, Kreacic M, Despotovic N etal. The Principles of chemotherapy of colorectal cancer in elderly. Adv Gerontol 2007; 20: 75-78.
21. Sargent DJ, Goldberg RM, Jacobson SD etal. A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med 2001; 345: 1091-1097.
22. Kim J-Y, Kim YJ, Lee K-W etal. Practical outcome of adjuvant folfox4 chemotherapy in elderly patients with stage iii colon cancer: single-center study in Korea. Jpn J Clin Oncol 2013; 43: 132-138.
23. Wehler TC, Cao Y, Galle PR etal. Combination therapies with oxaliplatin and oral capecitabine or intravenous 5-FU show similar toxicity profiles in gastrointestinal carcinoma patients if hand-food syndrome prophylaxis is performed continuously. Oncol Lett 2012; 3: 1191-1194.
24. Lindsay CR, Cassidy J. XELOX in colorectal cancer: a convenient option for the future? Expert Rev Gastroenterol Hepatol 2011; 5: 9-19.